Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review
Iranian Journal of Blood and Cancer,
Год журнала:
2024,
Номер
16(2), С. 84 - 101
Опубликована: Июнь 1, 2024
Язык: Английский
Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors
Small,
Год журнала:
2024,
Номер
20(19)
Опубликована: Фев. 7, 2024
Abstract
Immunotherapy
has
emerged
as
a
potent
strategy
in
cancer
treatment,
with
many
approved
drugs
and
modalities
the
development
stages.
Despite
its
promise,
immunotherapy
is
not
without
limitations,
including
side
effects
suboptimal
efficacy.
Using
nanoparticles
(NPs)
delivery
vehicles
to
target
lymph
nodes
(LNs)
can
improve
efficacy
of
reduce
patients.
In
this
context,
paper
reviews
LN‐targeted
immunotherapeutic
NP
strategies,
mechanisms
transport
during
LN
targeting,
their
related
biosafety
risks.
targeting
LNs
involves
either
passive
influenced
by
physical
properties,
or
active
facilitated
affinity
ligands
on
surfaces,
while
alternative
methods,
such
intranodal
injection
high
endothelial
venule
(HEV)
have
uncertain
clinical
applicability
require
further
research
validation.
NPs
for
increase
biocompatibility,
but
risks
toxicity,
organ
accumulation,
oxidative
stress
remain,
although
strategies
biodegradable
biomacromolecules,
polyethylene
glycol
(PEG)
coating,
impurity
addition
mitigate
these
Additionally,
work
concludes
future‐oriented
discussion,
offering
critical
insights
into
field.
Язык: Английский
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Signal Transduction and Targeted Therapy,
Год журнала:
2025,
Номер
10(1)
Опубликована: Март 5, 2025
The
successful
approval
of
peptide-based
drugs
can
be
attributed
to
a
collaborative
effort
across
multiple
disciplines.
integration
novel
drug
design
and
synthesis
techniques,
display
library
technology,
delivery
systems,
bioengineering
advancements,
artificial
intelligence
have
significantly
expedited
the
development
groundbreaking
drugs,
effectively
addressing
obstacles
associated
with
their
character,
such
as
rapid
clearance
degradation,
necessitating
subcutaneous
injection
leading
increasing
patient
discomfort,
ultimately
advancing
translational
research
efforts.
Peptides
are
presently
employed
in
management
diagnosis
diverse
array
medical
conditions,
diabetes
mellitus,
weight
loss,
oncology,
rare
diseases,
additionally
garnering
interest
facilitating
targeted
platforms
advancement
vaccines.
This
paper
provides
an
overview
present
market
clinical
trial
progress
therapeutics,
platforms,
It
examines
key
areas
through
literature
analysis
emphasizes
structural
modification
principles
well
recent
advancements
screening,
design,
technologies.
accelerated
including
peptide-drug
complexes,
new
vaccines,
innovative
diagnostic
reagents,
has
potential
promote
era
precise
customization
disease
therapeutic
schedule.
Язык: Английский
Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy
Advanced Healthcare Materials,
Год журнала:
2024,
Номер
13(13)
Опубликована: Фев. 7, 2024
Cancer
nanovaccines
have
attracted
widespread
attention
by
inducing
potent
cytotoxic
T
cell
responses
to
improve
immune
checkpoint
blockade
(ICB)
therapy,
while
the
lack
of
co-stimulatory
molecules
limits
their
clinical
applications.
Here,
a
genetically
engineered
cancer
cytomembrane
nanovaccine
is
reported
that
simultaneously
overexpresses
molecule
CD40L
and
inhibitor
PD1
elicit
robust
antitumor
immunity
for
immunotherapy.
The
tumor
antigens
inherited
from
cytomembranes
effectively
stimulate
dendritic
(DC)-mediated
activation
cells,
on
significantly
blocks
PD1/PD-L1
signaling
pathway,
synergistically
stimulating
responses.
Benefiting
targeting
ability
cytomembranes,
this
formula
shows
an
enhanced
lymph
node
trafficking
retention.
Compared
with
original
induces
twofold
DC
maturation
satisfactory
precaution
efficacy
in
breast
mouse
model.
This
offers
simple,
safe,
strategy
incorporating
components
Язык: Английский
Next generation CD40 agonists for cancer immunotherapy
Expert Opinion on Biological Therapy,
Год журнала:
2024,
Номер
24(5), С. 351 - 363
Опубликована: Май 3, 2024
Introduction
There
is
a
need
for
new
therapies
that
can
enhance
response
rates
and
broaden
the
number
of
cancer
indications
where
immunotherapies
provide
clinical
benefit.
CD40
targeting
an
opportunity
to
meet
this
by
promoting
priming
tumor-specific
T
cells
reverting
suppressive
tumor
microenvironment.
This
supported
emerging
evidence
demonstrating
benefits
immunotherapy
with
antibodies
in
combination
standard
care
chemotherapy.
Язык: Английский
Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives
Computational and Structural Biotechnology Journal,
Год журнала:
2024,
Номер
23, С. 1833 - 1843
Опубликована: Апрель 21, 2024
Preventive
cancer
vaccines
are
highly
effective
in
preventing
viral
infection-induced
cancer,
but
advances
therapeutic
with
a
focus
on
eliminating
cells
through
immunotherapy
limited.
To
develop
vaccines,
the
integration
of
optimal
adjuvants
is
potential
strategy
to
enhance
or
complement
existing
approaches.
However,
conventional
do
not
satisfy
criteria
clinical
trials
for
vaccines.
improve
effects
vaccination
strategies
must
be
formulated
and
novel
identified.
This
review
offers
an
overview
current
advancements
highlights
situ
approaches
that
can
synergistically
combined
other
immunotherapies
by
harnessing
adjuvant
effects.
Additionally,
refinement
systems
using
cutting-edge
technologies
elucidation
molecular
mechanisms
underlying
immunogenic
cell
death
facilitate
development
innovative
have
been
discussed.
study
lies
providing
crucial
insights
into
applications
designing
more
thereby
facilitating
application
tumor
promote
death.
Язык: Английский
Tumor Microenvironment Sequential Drug/Gene Delivery Nanosystem for Realizing Multistage Boosting of Cancer–Immunity Cycle on Cancer Immunotherapy
Yongjing Cao,
Juan Li,
Qiangwei Liang
и другие.
ACS Applied Materials & Interfaces,
Год журнала:
2023,
Номер
15(47), С. 54898 - 54914
Опубликована: Ноя. 14, 2023
The
antitumor
immune
response
of
cancer
immunotherapy
is
a
cascade
cancer-immunity
cycles
(CIC).
immunosuppression
the
tumor
microenvironment
and
low
immunogenicity
cells,
insufficient
T
lymphocyte
activation,
trafficking,
infiltration
caused
failure
to
initiate
run
continuous
multistage
CIC,
leading
unsatisfactory
outcomes.
A
doxorubicin/interleukin-12
plasmid
DNA/celecoxib
(DOX/pIL-12/CXB)
combination
strategy
was
designed
by
targeting
CIC.
Then,
an
intratumoral
CXB-detachable
nanosystem,
or
DOX/PAC/pIL-12
micelleplexes,
developed
for
sequential
drug/gene
delivery
facilitate
boosting
CIC
on
synergistic
immunotherapy.
micelleplexes
could
program
intratumorally
release
CXB
remodulate
suppressing
cyclooxygenase-2/prostaglandin
E2
(COX-2/PGE2)
pathway.
smaller
sizes
surface
charge-switched
facilitated
codelivery
corelease
DOX
pIL-12
inside
4T1
cells.
These
exerted
using
activation
amplification,
providing
therapeutic
antimetastasis
efficacy.
nanosystem
provides
complete
CIC-boosted
combinatory
developing
against
cancer.
Язык: Английский
Nanocarrier design for pathogen-inspired innate immune agonist delivery
Trends in Immunology,
Год журнала:
2024,
Номер
45(9), С. 678 - 692
Опубликована: Авг. 26, 2024
In
complex
diseases
such
as
cancer,
modulating
cytokine
signatures
of
disease
using
innate
immune
agonists
holds
therapeutic
promise.
Novel
multi-agonist
treatments
offer
tunable
control
the
system
because
they
are
uniquely
pathogen
inspired,
eliciting
robust
antitumor
responses
by
promoting
synergistic
responses.
However,
chief
strategic
hurdle
is
ensuring
delivery
to
same
target
cells,
highlighting
importance
nanomaterial-based
carriers.
Here,
we
place
nanocarriers
in
center
stage
and
review
hurdles
related
varying
extra-
intracellular
localizations
receptors.
We
discuss
a
range
nanomaterials
used
for
delivery,
their
respective
benefits
drawbacks.
Our
overarching
stance
that
rational
nanocarrier
design
crucial
developing
pathogen-inspired
immunotherapies.
Язык: Английский